ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic value of circulating HER2 extracellular domain in patients with HER2-positive metastatic breast carcinoma treated with TDM-1 (trastuzumab emtansine).
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibody-drug conjugates (ADC) improved survival in patients with HER2-positive MBC. To date, there is no prognostic biomarker in routine practice for these patients. HER2-ECD is associated with poor prognosis but has not yet been studied in patients receiving ADC.
methodsThis monocentric retrospective study assessed in HER2-positive MBC patients shows the prognostic value on OS and PFS of (1) baseline HER2-ECD and CA15-3 and (2) HER2-ECD and CA15-3 after 3 months of treatment with TDM-1. At baseline, patients were divided according to the median value of HER2-ECD and CA15-3 from study population. For kinetic assessments, we compared survival outcomes according to the evolution of HER2-ECD and CA15-3 (stable/decrease vs increase).
results40 patients were included. For both biomarkers, baseline values were not prognostic for OS neither PFS. Patients with stable or decrease HER2-ECD at 3 months had a significantly longer OS (median 43 versus 15.3 months, p < 0.0001) and PFS (median 9.4 versus 2.9 months, p = 0.0018) than patients with decrease, confirmed in multivariate analysis (p = 0.004 for OS and < 0.0001 for PFS). In contrast, CA15-3 kinetic was only prognostic for PFS (median 9.6 versus 4.9 months, p = 0.019), confirmed in multivariate analysis (p = 0.008).
conclusionIn this retrospective cohort, HER2-ECD kinetic was a prognostic biomarker for OS and PFS in patients with an HER2-positive MBC treated with TDM-1.
Indexed as
Identifiers
40754555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.